Combination of Serum KL-6 and Immune/Inflammatory Markers for Identifying Complicated Silicosis
By
Rui He
Limin Huang
Yang Chen
Minqi Liu
Miaomiao Xie
Honglei Yuan
Ling Mao
January 3, 2026
Clinical Scorecard: Combination of Serum KL-6 and Immune/Inflammatory Markers for Identifying Complicated Silicosis
At a Glance
Category Detail
Condition Key Mechanisms Target Population Occupational dust-exposed individuals, particularly in high-risk occupations such as stone cutting and sandblasting. Care Setting
Key Highlights
KL-6 is a promising biomarker for early diagnosis of silicosis. Complicated silicosis is characterized by coalescent nodules > 1 cm and rapid progression. Current diagnostic methods have limitations in sensitivity and applicability. Inflammatory cytokines may enhance the diagnostic utility of KL-6. Silicosis remains a significant public health issue in developing countries. The interaction between KL-6 and inflammatory cytokines may provide additional diagnostic insights. Guideline-Based Recommendations
Diagnosis
Use chest radiography and HRCT for diagnosing silicosis. Diagnose based on profusion category 1 opacities in at least two lung zones. Management
Monitor serum KL-6 and inflammatory markers for disease progression. Consider the role of HRCT and PFTs in ongoing monitoring. Monitoring & Follow-up
Regular pulmonary function tests and serum biomarker assessments. Risks
Higher comorbidity and mortality rates associated with complicated silicosis. Patient & Prescribing Data
No prior antifibrotic medication use among participants; focus on biomarker monitoring, which may influence future treatment strategies.
Clinical Best Practices
Implement non-invasive serum biomarker testing for early detection. Utilize a multidisciplinary team for accurate diagnosis and management. Ensure regular follow-up and monitoring of lung function in at-risk populations. Integrate KL-6 monitoring into routine clinical assessments. References
